{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:52:47Z","timestamp":1761630767361},"reference-count":0,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background and Aims: In this pilot study, we assessed the safety and tolerability of combining sorafenib with 90Y radioembolization for the treatment of unresectable hepatocellular carcinoma (HCC). Methods: The study, conducted prospectively during 2009\u20132012, included eligible patients with unresectable HCC and a life expectancy of at least 12 weeks. Each patient received sorafenib (400 mg twice daily) for 6\u20138 weeks before 90Y treatment. Safety and tolerability were assessed. Results: Of the 40 patients enrolled, 29 completed treatment (combined therapy). In the initial cohort, the most common cause of HCC was hepatitis C (32.5%), and most patients were staged Child A (82.5%). The 29 patients who completed the study had similar baseline characteristics. Grades 1 and 2 toxicities accounted for 77.8% of all adverse events reported. The most common toxicities reported were fatigue (19.0%), alteration in liver function (7.9%), and diarrhea (6.3%). There were 12 grade 3 and 2 grade 4 toxicity events reported. One patient died of liver failure within 30 days after treatment. During the study, the sorafenib dose was reduced in 6 patients (20.7%), and sorafenib had to be interrupted in 4 patients (13.8%) and discontinued in 4 patients (13.8%). The disease control rate was 72.4% per the modified Response Evaluation Criteria in Solid Tumors, and tumour necrosis was observed in 82.8% of patients. Overall survival in patients undergoing combined therapy was 12.4 months. Conclusions: Preliminary results demonstrate the safety and tolerability of combining 90Y radioembolization and sorafenib for advanced HCC. A larger prospective study is needed to determine the extent of the survival benefit.<\/jats:p>","DOI":"10.3747\/co.23.2827","type":"journal-article","created":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T19:19:16Z","timestamp":1477509556000},"page":"472-480","source":"Crossref","is-referenced-by-count":12,"title":["Combined Sorafenib and Yttrium-90 Radioembolization for the Treatment of Advanced Hepatocellular Carcinoma"],"prefix":"10.3390","volume":"23","author":[{"given":"A.","family":"Salman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Simoneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hassanain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Chaudhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.M.","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Nudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Metrakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2016,10,1]]},"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.current-oncology.com\/index.php\/oncology\/article\/viewFile\/2827\/2243","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.current-oncology.com\/index.php\/oncology\/article\/viewFile\/2827\/2272","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mdpi.com\/1718-7729\/23\/5\/2827\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T08:05:57Z","timestamp":1613721957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/23\/5\/2827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,1]]},"references-count":0,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,10]]}},"alternative-id":["co.23.2827"],"URL":"https:\/\/doi.org\/10.3747\/co.23.2827","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,1]]}}}